SOT 58th Annual Meeting & ToxExpo – 1780 Poster Presentation by Dr Shraddha Thakker of the FDA NCTR

At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, poster presentation by Dr Shraddha Thakker of the FDA NCTR on Tuesday March 12th 10:45am - 12:15pm Poster Board P156 Convention Center Exhibition Hall.  Drug-Induced Liver Injury Severity and Toxicity (DILIst): Binary Classification of 1379 Drugs by [...]

By |2019-03-07T13:54:13+00:00March 7th, 2019|Toxicology, Events|Comments Off on SOT 58th Annual Meeting & ToxExpo – 1780 Poster Presentation by Dr Shraddha Thakker of the FDA NCTR

SOT 58th Annual Meeting & ToxExpo – 2072: Poster Presentation by Richard Printemps of PhysioStim

At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, poster presentation by Richard Printemps of PhysioStim on Tuesday March 12th 3:00pm - 4:30pm Poster Board P463 Convention Center Exhibition Hall.  Incorporating the CiPA Paradigm into an Integrated Cardiac Risk Assessment. Authors:  M. Morton1, R. Printemps2, M. [...]

By |2019-03-05T14:42:32+00:00March 5th, 2019|Ion Channels, Events|Comments Off on SOT 58th Annual Meeting & ToxExpo – 2072: Poster Presentation by Richard Printemps of PhysioStim

SOT 58th Annual Meeting & ToxExpo – 2613: Talk by Dr Paul Duffy of ApconiX

At the Society of Toxicology 58th Annual Meeting and ToxExpo from March 10th to 14th at the Baltimore Convention Center, Dr Paul Duffy of ApconiX will be giving a talk as part of the Safety Assessment: Pharmaceutical—Drug Development I Platform on Wednesday March 13th 9:15am – 9:30am in Convention Center Room 321. New Opportunities for a Psychoactive Psilocybin in [...]

By |2019-03-04T17:31:07+00:00March 4th, 2019|Toxicology, Events|Comments Off on SOT 58th Annual Meeting & ToxExpo – 2613: Talk by Dr Paul Duffy of ApconiX

Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]

By |2018-07-11T10:12:48+01:00March 27th, 2018|Toxicology|Comments Off on Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+01:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure